SAN DIEGO--(BUSINESS WIRE)--Sep. 28, 2017--
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, announced that it has received notice from
the Federal Trade Commission granting early termination of the waiting
period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976,
as amended, with respect to Quidel’s pending acquisition of Alere Inc.’s
Triage B-type natriuretic peptide assay business run on Beckman Coulter
analyzers (the “BNP business”). The acquisition of the BNP business by
Quidel remains subject to the completion of Abbott’s acquisition of
Alere, as well as other regulatory approvals and other customary closing
conditions.
Quidel’s acquisition of Alere’s Triage MeterPro business is not affected
by the early termination of the waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, and remains
subject to the completion of Abbott’s acquisition of Alere, as well as
regulatory approvals and other customary closing conditions.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being of people
around the globe through the development of diagnostic solutions that
can lead to improved patient outcomes and provide economic benefits to
the healthcare system. Marketed under the Sofia®, QuickVue®, D3® Direct
Detection, Thyretain® and InflammaDry® leading brand names, as well as
under the new Solana®, AmpliVue® and Lyra® molecular diagnostic brands,
Quidel’s products aid in the detection and diagnosis of many critical
diseases and conditions, including, among others, influenza, respiratory
syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal
occult blood. Quidel’s research and development engine is also
developing a continuum of diagnostic solutions from advanced
lateral-flow and direct fluorescent antibody to molecular diagnostic
tests to further improve the quality of healthcare in physicians’
offices and hospital and reference laboratories. For more information
about Quidel’s comprehensive product portfolio, visit quidel.com.
Forward-Looking Statements
This press release contains certain forward-looking statements. These
matters are subject to risks and uncertainties that could cause actual
results to differ materially from those projected, anticipated or
implied. These risks and uncertainties include: the ability to
successfully consummate the Company’s acquisition of the BNP business,
and the related pending acquisition of Alere’s Triage® MeterPro assets
(collectively, the “acquisitions”) on a timely basis, if at all,
including the satisfaction of the closing conditions of the acquisitions
(including consummation of Abbott’s acquisition of Alere); the ability
to receive all other regulatory approvals for the acquisitions on a
timely basis, if at all; the ability to satisfy the conditions of and
obtain financing to complete the acquisition of the Triage® MeterPro
assets (the “Triage business”); the conditions of the credit markets and
the Company’s ability to fund the acquisitions on acceptable terms; the
risk that disruptions will occur from the acquisitions that will harm
the Company’s business, the Triage business or the BNP business; any
disruptions or threatened disruptions to the relationships of the
Company, the Triage business or the BNP business with their respective
distributors, suppliers, customers and employees; the Company’s ability
to manage the foreign expansion; the receipt of regulatory approvals or
clearances relating to the Triage business or the BNP business, or any
loss of previously received regulatory approvals or clearances; a
significant reduction in sales of the Triage business or BNP business,
or increase in costs, expenses or other charges incurred by, relating to
or arising from such businesses; the inability to achieve anticipated
financial results from the acquired businesses; and the Company’s
ability to successfully integrate the acquired businesses into the
Company’s operations, including its ability to realize anticipated
synergies and operational improvement. Forward-looking statements
are based on management’s expectations as well as estimates and
assumptions prepared by management that, although they believe to be
reasonable, are inherently uncertain. The Company is subject to
additional risks and uncertainties described in the Company’s annual
report on Form 10-K and subsequent quarterly reports on Form 10-Q. You
are cautioned not to place undue reliance on these forward-looking
statements, which reflect management’s analysis and expectations only as
of the date of this press release. We undertake no obligation to
publicly release the results of any revision or update of the
forward-looking statements, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170928006191/en/
Source: Quidel Corporation
For Quidel Corporation
Randy Steward
Chief Financial Officer
(858)
552-7931
or
Angie Mazza
(312) 690-6006
amazza@clermontpartners.com